Compare · LLY vs THTX
LLY vs THTX
Side-by-side comparison of Eli Lilly and Company (LLY) and Theratechnologies Inc. (THTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LLY and THTX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.06T, about 3676.1x THTX ($287.3M).
- Over the past year, LLY is up 45.8% and THTX is up 7.4% - LLY leads by 38.4 points.
- LLY has hit the wire 13 times in the past 4 weeks while THTX has been quiet.
- LLY has more recent analyst coverage (25 ratings vs 2 for THTX).
- Company
- Eli Lilly and Company
- Theratechnologies Inc.
- Price
- $1121.18-2.41%
- $3.40+0.30%
- Market cap
- $1.06T
- $287.3M
- 1M return
- -7.40%
- +4.46%
- 1Y return
- +45.82%
- +7.44%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 13
- 0
- Recent ratings
- 25
- 2
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Theratechnologies Inc.
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH-1902 for the treatment of triple negative breast cancer; and TH-1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.
Latest LLY
- EVP, Global Quality Seymour Melissa converted options into 981 shares and covered exercise/tax liability with 439 shares, increasing direct ownership by 103% to 1,067 units (SEC Form 4)
- Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer
- New insider Eli Lilly & Co claimed ownership of 1,054,828 shares (SEC Form 3)
- Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C
- Lilly confirms date and conference call for second-quarter 2026 financial results announcement
- Director Sulzberger Gabrielle was granted 4 shares, increasing direct ownership by 0.14% to 3,000 units (SEC Form 4)
- Director Luciano Juan R was granted 14 shares, increasing direct ownership by 0.08% to 16,905 units (SEC Form 4)
- Director Fyrwald J Erik was granted 9 shares, increasing direct ownership by 0.01% to 75,410 units (SEC Form 4)
- Director Alvarez Ralph was granted 11 shares, increasing direct ownership by 0.02% to 55,734 units (SEC Form 4)
- Billions Flow Into Next-Generation Depression Treatments as Pharma Innovation Accelerates
Latest THTX
- Amendment: SEC Form SCHEDULE 13G/A filed by Theratechnologies Inc.
- SEC Form 25-NSE filed by Theratechnologies Inc.
- SEC Form 6-K filed by Theratechnologies Inc.
- Theratechnologies Announces Completion of Acquisition by Future Pak
- SEC Form 6-K filed by Theratechnologies Inc.
- Theratechnologies Receives Final Court Approval of Proposed Plan of Arrangement to Be Acquired by Future Pak
- SEC Form 6-K filed by Theratechnologies Inc.
- SEC Form 6-K filed by Theratechnologies Inc.
- Theratechnologies Shareholders Approve Proposed Plan of Arrangement to Be Acquired by Future Pak
- SEC Form 6-K filed by Theratechnologies Inc.